Browse by category

Eli Lilly and Company has announced an agreement with the US government to expand access to its obesity medicines and reduce patient costs. In 2020, Lilly partnered with the Trump Administration on a pilot programme that paved the way for Lilly to be the first company to cap out-of-pocket insulin costs at $35 per month. Lilly will now improve access to nearly 40 million Americans living with obesity on government insurance programmes and millions more who pay out-of-pocket. U

Nitinotes has received CE Mark approval for the EndoZip System, the first fully automated suturing platform for endoscopic sleeve gastroplasty (ESG). The milestone clearance enables the company to begin commercialisation across the European Union and other CE Mark-accepting markets. Nitinotes will launch EndoZip in select European centres of excellence, building clinical adoption and real-world data to support broader market penetration. In parallel, the company is preparing

Novo Nordisk has received FDA approval for Rybelsus for reducing the risk of major adverse cardiovascular events (MACE) such as cardiovascular (CV) death, heart attack, or stroke in adults with type 2 diabetes who are at high risk for these events, whether they've had a prior CV event or not (primary and secondary prevention). Results of the SOUL trial reinforce the clinical profile of the semaglutide molecule, which has been studied across a variety of therapeutic areas. "Ev

Medtimo, a wholly owned subsidiary of Biorad Medisys Private Limited, has filed a patent infringement complaint in the US District Court of the District of Delaware against Allurion Technologies. Medtimo’s complaint claims Allurion's gastric balloon system infringes upon Medtimo's intellectual property. This definitive action follows Allurion’s recent unsuccessful challenge of Medtimo’s patent rights in the US Patent and Trademark Office (USPTO). The complaint alleges that Al

Pfizer and Metsera have entered into a definitive agreement under which Pfizer will acquire Metsera, a clinical-stage biopharmaceutical...

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has approved an update to Novo Nordisk’s...

Bariatric News  spoke with Dr Carlos Gomez (International Specialist Center International Hospital of Colombia, Bucaramanga, Colombia)...